Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    semorinemab
Previous Study | Return to List | Next Study

A Study of Semorinemab in Patients With Moderate Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03828747
Recruitment Status : Active, not recruiting
First Posted : February 4, 2019
Last Update Posted : October 20, 2021
Sponsor:
Information provided by (Responsible Party):
Genentech, Inc.

Tracking Information
First Submitted Date  ICMJE January 29, 2019
First Posted Date  ICMJE February 4, 2019
Last Update Posted Date October 20, 2021
Actual Study Start Date  ICMJE January 30, 2019
Actual Primary Completion Date July 20, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 7, 2020)
  • Change From Baseline to Last Visit of Double-Blind Treatment Period in Cognitive Function as Measured by the Alzheimer's Disease Assessment Scale, Cognitive Subscale, 11-Item Version (ADAS-Cog11) [ Time Frame: Baseline to Week 49 for Cohort 1, Baseline to Week 61 for Cohort 2, and baseline to Week 73 for Cohort 3 ]
    A 70-point scale used to quantify the areas of cognitive function most often affected in Alzheimer's disease. Lower scores indicate better cognitive function.
  • Change From Baseline to Last Visit of Double-Blind Treatment Period in Functional Capacities as Measured by the Alzheimer's Disease Cooperative Study-Daily Living Inventory (ADCS-ADL) [ Time Frame: Baseline to Week 49 for Cohort 1, Baseline to Week 61 for Cohort 2, and baseline to Week 73 for Cohort 3 ]
    A scale used to quantify performance of activities of daily living. Scores on the ADCS-ADL range from 0-78, with higher scores indicating better ADL function.
Original Primary Outcome Measures  ICMJE
 (submitted: January 31, 2019)
  • Change from baseline to Week 49 in cognitive function as measured by the Alzheimer's Disease Assessment Scale, Cognitive Subscale, 11-item version (ADAS-Cog11) [ Time Frame: Baseline to Week 49 ]
    A 70-point scale used to quantify the areas of cognitive function most often affected in Alzheimer's disease. Lower scores indicate better cognitive function.
  • Change from baseline to Week 49 in functional capacities as measured by the Alzheimer's Disease Cooperative Study-Daily Living Inventory (ADCS-ADL) [ Time Frame: Baseline to Week 49 ]
    A scale used to quantify performance of activities of daily living. Scores on the ADCS-ADL range from 0-78, with higher scores indicating better ADL function.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 7, 2020)
  • Change From Baseline to Last Visit of Double-Blind Treatment Period on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) [ Time Frame: Baseline to Week 49 for Cohort 1, Baseline to Week 61 for Cohort 2, and baseline to Week 73 for Cohort 3 ]
    A scale used to quantify the severity of symptoms of dementia. The CDR-SB is obtained through interviews of patients and informants, and disease severity is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a 5-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment (personal care is scored on a 4-point scale without a 0.5 rating available). The CDR-SOB score is obtained by summing each of the domain box scores, with scores ranging from 0 to 18, with the higher values representing more severe impairment.
  • Change From Baseline to Last Visit of Double-Blind Treatment Period on the Mini-Mental State Examination (MMSE) [ Time Frame: Baseline to Week 49 for Cohort 1, Baseline to Week 61 for Cohort 2, and baseline to Week 73 for Cohort 3 ]
    The Mini Mental State Examination (MMSE) is a brief clinical cognitive examination commonly used to screen for dementia and other cognitive deficits that has a total score of 0-30. Higher scores indicate better cognitive function.
  • Percentage of Participants with Adverse Events [ Time Frame: Up to approximately 73 months ]
  • Serum concentration of RO7105705 at specified timepoints [ Time Frame: Weeks 1,3,5,9,13,25,37,49,& at treatment discontinuation (up to Week 48) for C1. Weeks 1,3,5,9,13,25,37,49,61,& at treatment discontinuation (up to Week 60) for C2. Weeks 1,3,5,9,13,25,37,49,61,73,& at treatment discontinuation (up to Week 72) for C3. ]
    C=Cohort
  • Incidence of anti-drug antibodies (ADAs) during the study relative to the prevalence of ADAs at baseline [ Time Frame: Weeks 1,13,25,37,49,& at treatment discontinuation (up to Week 48) for Cohort 1. Weeks 1,13,25,37,49,61,& at treatment discontinuation (up to Week 60) for Cohort 2. Weeks 1,13,25,37,49,61,73,& at treatment discontinuation (up to Week 72) for Cohort 3. ]
  • Relationship between ADA Status and Percentage of Participants with Adverse Events [ Time Frame: Up to approximately 73 months ]
    Descriptive statistics will be used for assessment.
  • Relationship Between ADA Status and Change From Baseline to Last Visit of Double-Blind Treatment Period in Cognitive Function as Measured by the Alzheimer's Disease Assessment Scale, Cognitive Subscale, 11-Item Version (ADAS-Cog11) [ Time Frame: Baseline to Week 49 for Cohort 1, Baseline to Week 61 for Cohort 2, and baseline to Week 73 for Cohort 3 ]
    Descriptive statistics will be used for assessment. A 70-point scale used to quantify the areas of cognitive function most often affected in Alzheimer's disease. Lower scores indicate better cognitive function.
  • Relationship Between ADA Status and Change From Baseline to Last Visit of Double-Blind Treatment Period in Functional Capacities as Measured by the Alzheimer's Disease Cooperative Study-Daily Living Inventory (ADCS-ADL) [ Time Frame: Baseline to Week 49 for Cohort 1, Baseline to Week 61 for Cohort 2, and baseline to Week 73 for Cohort 3 ]
    Descriptive statistics will be used for assessment. A scale used to quantify performance of activities of daily living. Scores on the ADCS-ADL range from 0-78, with higher scores indicating better ADL function.
  • Relationship Between ADA Status and Change From Baseline to Last Visit of Double-Blind Treatment Period on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) [ Time Frame: Baseline to Week 49 for Cohort 1, Baseline to Week 61 for Cohort 2, and baseline to Week 73 for Cohort 3 ]
    Descriptive statistics will be used for assessment. A scale used to quantify the severity of symptoms of dementia. The CDR-SB is obtained through interviews of patients and informants, and disease severity is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a 5-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment (personal care is scored on a 4-point scale without a 0.5 rating available). The CDR-SOB score is obtained by summing each of the domain box scores, with scores ranging from 0 to 18, with the higher values representing more severe impairment.
  • Relationship Between ADA Status and Change From Baseline to Last Visit of Double-Blind Treatment Period on the Mini-Mental State Examination (MMSE) [ Time Frame: Baseline to Week 49 for Cohort 1, Baseline to Week 61 for Cohort 2, and baseline to Week 73 for Cohort 3 ]
    Descriptive statistics will be used for assessment. The Mini Mental State Examination (MMSE) is a brief clinical cognitive examination commonly used to screen for dementia and other cognitive deficits that has a total score of 0-30. Higher scores indicate better cognitive function.
  • Relationship Between ADA Status and Serum Concentration of RO7105705 at Specified Timepoints [ Time Frame: Weeks 1,13,25,37,49,&at treatment discontinuation (up to Week 48) for Cohort 1. Weeks 1,13,25,37,49,61,&at treatment discontinuation (up to Week 60) for Cohort 2. Weeks 1,13,25,37,49,61,73,&at treatment discontinuation (up to Week 72) for Cohort 3. ]
    Descriptive statistics will be used for assessment.
  • Relationship Between ADA Status and Incidence of Anti-Drug Antibodies (ADAs) During the Study Relative to the Prevalence of ADAs at Baseline [ Time Frame: Weeks 1,13,25,37,49, & at treatment discontinuation (up to Week 48) for Cohort 1. Weeks 1,13,25,37,49,61, & at treatment discontinuation (up to Week 60) for Cohort 2. Weeks 1,13,25,37,49,61,73,& at treatment discontinuation (up to Week 72) for Cohort 3. ]
    Descriptive statistics will be used for assessment.
Original Secondary Outcome Measures  ICMJE
 (submitted: January 31, 2019)
  • Change from baseline to Week 49 on the Clinical Dementia Rating-Sum of Boxes (CDR-SB) [ Time Frame: Baseline to Week 49 ]
    A scale used to quantify the severity of symptoms of dementia. The CDR-SB is obtained through interviews of patients and informants, and disease severity is rated in 6 domains of functioning: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care. Each domain is rated on a 5-point scale of functioning as follows: 0, no impairment; 0.5, questionable impairment; 1, mild impairment; 2, moderate impairment; and 3, severe impairment (personal care is scored on a 4-point scale without a 0.5 rating available). The CDR-SOB score is obtained by summing each of the domain box scores, with scores ranging from 0 to 18, with the higher values representing more severe impairment.
  • Change from baseline to Week 49 on the Mini-Mental State Examination (MMSE) [ Time Frame: Baseline to Week 49 ]
    The Mini Mental State Examination (MMSE) is a brief clinical cognitive examination commonly used to screen for dementia and other cognitive deficits that has a total score of 0-30. Higher scores indicate better cognitive function.
  • Percentage of Participants with Adverse Events [ Time Frame: Up to approximately 51 months ]
  • Serum concentration of MTAU9937A at specified timepoints [ Time Frame: Weeks 1, 3, 5, 9, 13, 25, 37, and 49, and at treatment discontinuation (up to week 48) ]
  • Incidence of anti-drug antibodies (ADAs) during the study relative to the prevalence of ADAs at baseline [ Time Frame: Weeks 1, 13, 25, 37 and 49, and at treatment discontinuation (up to week 48) ]
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE A Study of Semorinemab in Patients With Moderate Alzheimer's Disease
Official Title  ICMJE A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy, and Safety Study of MTAU9937A in Patients With Moderate Alzheimer's Disease
Brief Summary This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study will evaluate the clinical efficacy, safety, pharmacokinetics, and pharmacodynamics of semorinemab in patients with moderate AD. The study consists of a screening period, a double-blind treatment period, an optional open-label extension (OLE) period, and a safety follow-up period. There may be up to three study cohorts.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Alzheimer's Disease
Intervention  ICMJE
  • Drug: Semorinemab
    Participants will receive semorinemab every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period. Semorinemab will be administered Q4W in the OLE period.
    Other Names:
    • MTAU9937A
    • RO7105705
  • Drug: Placebo
    Participants will receive placebo every 2 weeks (Q2W) for the first three doses of the double-blind treatment period and every 4 weeks (Q4W) thereafter during the double-blind treatment period.
  • Drug: [18F]GTP1
    [18F]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
Study Arms  ICMJE
  • Experimental: Semorinemab
    Semorinemab will be administered intravenously in the double-blind treatment period, and semorinemab will be administered in the optional open-label extension period.
    Interventions:
    • Drug: Semorinemab
    • Drug: [18F]GTP1
  • Placebo Comparator: Placebo
    Placebo will be administered intravenously in the double-blind treatment period.
    Interventions:
    • Drug: Placebo
    • Drug: [18F]GTP1
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: October 18, 2021)
273
Original Estimated Enrollment  ICMJE
 (submitted: January 31, 2019)
260
Estimated Study Completion Date  ICMJE October 20, 2023
Actual Primary Completion Date July 20, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • National Institute on Aging/Alzheimer's Association core clinical criteria for probable AD dementia
  • Evidence of the AD pathological process, by a positive amyloid assessment either on CSF Aβ1-42 as measured on Elecsys β-Amyloid(1-42) Test System OR amyloid PET scan
  • AD dementia of moderate severity, as defined by a screening MMSE score of 16-21 points, inclusive, and a CDR-GS of 1 or 2
  • Availability of a person with sufficient contact with the participant to be able to provide accurate information on the participant's cognitive, behavioral and functional ability

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Inability to tolerate MRI procedures or contraindication to MRI
  • Contraindication to PET imaging
  • Residence in a skilled nursing facility
  • Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or bias the assessment of the clinical or mental status of the participant to a significant degree
  • Any evidence of a condition other than AD that may affect cognition
  • Substance abuse within the past 2 years
  • Use of any experimental therapy within 90 days or 5 half-lives prior to screening, whichever is greater, or any passive immunotherapy against tau
  • Use of any passive immunotherapy (immunoglobulin) against Aβ, unless the last dose was at least 1 year prior to screening or any active immunotherapy (vaccine) that is under evaluation to prevent or postpone cognitive decline
  • Any other biologic therapy or previous treatment with medications specifically intended to treat Parkinsonian symptoms or any other non-AD neurodegenerative disorder within 1 year of screening
  • Systemic immunosuppressive therapy within 12 months of screening through the entire study period
  • Typical antipsychotic or neuroleptic medication within 6 months of screening
  • Daily treatment with any of the following classes of medication (except for intermittent short-term use): opiates or opioids, benzodiazepines, barbiturates, hypnotics, or any medication with clinically significant centrally-acting antihistamine or anticholinergic activity
  • Stimulant medications, unless the dose has been stable within the 6 months prior to screening and is expected to be stable throughout the study
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 50 Years to 85 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE France,   Poland,   Spain,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03828747
Other Study ID Numbers  ICMJE GN40040
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Yes
Plan Description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.clinicalstudydatarequest.com). Further details on Roche's criteria for eligible studies are available here (https://clinicalstudydatarequest.com/Study-Sponsors/Study-Sponsors-Roche.aspx). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)
Responsible Party Genentech, Inc.
Study Sponsor  ICMJE Genentech, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director: Clinical Trials Hoffmann-La Roche
PRS Account Genentech, Inc.
Verification Date October 2021

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP